Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada Considers Extending Readiness Inspections To Non-COVID-19 Trials

Executive Summary

Health Canada’s early inspection program helps sponsors of COVID-19 clinical trials better identify gaps in their procedures before enrolling patients. It also provides intelligence on sites that may need to undergo a full GCP inspection later. 

You may also be interested in...



Roche’s Eye Drug Scores First UK Approval Under Access Consortium

The UK MHRA has approved its first drug under an international work-sharing initiative that also includes regulators from Australia, Canada, Singapore and Switzerland.

UK MHRA Specifies Eligibility For Consultancy Firms To Monitor GMP, GDP Compliance

Consultancy firms must have at least five years of experience in carrying out independent GMP or GDP audits if they want to apply to become a “compliance monitor” under a new MHRA scheme to keep track of drug companies that fail to comply with GMP/GDP requirements. 

Digital Data Deluge Can Affect Oversight Of Patient Safety In Trials

The digitalization of clinical trials is generating more patient safety data than companies can process. A senior EMA official says sponsors should carefully select what is needed to maintain appropriate subject oversight by “getting the science right.”

Topics

UsernamePublicRestriction

Register

PS145858

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel